Skip to content
value.today

Tetralogic Pharmaceuticals Corp.

Total raised
$28 M
5 rounds on record
Latest round
$5 M
Nov 2012
First round on record
Nov 2009
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Tetralogic Pharmaceuticals Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2012$5 MNo. 5$2 to $10 million

Tetralogic Pharmaceuticals Corp.: Raise no. 5, Nov 2012

Investors in this round

21 investors had bought by the notice of Dec 13, 2012: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Tetralogic Pharmaceuticals Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David E. Weng · Executive Officer
  • James E. Goldschmidt · Executive Officer
  • John M. Gill · Executive Officer, Director
  • Andrew E. Pecora · Director
  • Brenda E. Gavin · Director
  • Douglas E. Onsi · Director
  • Douglas E. Reed · Director
  • James E. Woody · Director
  • Michael E. Steinmetz · Director
  • Paul E. Schmitt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John M. Gill, President & CEO. Newest notice filed Dec 13, 2012. Read the notice at the SEC.

debt, optionsSEC
May 2011$6 MNo. 4$2 to $10 million

Tetralogic Pharmaceuticals Corp.: Raise no. 4, May 2011

Investors in this round

2 investors had bought by the notice of May 31, 2011: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Tetralogic Pharmaceuticals Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Helga A. Kautsky · Executive Officer
  • John M. Gill · Executive Officer, Director
  • Mark A. McKinlay · Executive Officer
  • Andrew A. Pecora · Director
  • Brenda A. Gavin · Director
  • Douglas A. Reed · Director
  • Harold A. Werner · Director
  • James A. Woody · Director
  • Michael A. Steinmetz · Director
  • Paul A. Schmitt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John M. Gill, President & CEO. Newest notice filed May 31, 2011. Read the notice at the SEC.

equitySEC
Jul 2010$13 MNo. 3$10 to $50 million

Tetralogic Pharmaceuticals Corp.: Raise no. 3, Jul 2010

Investors in this round

10 investors had bought by the notice of Aug 10, 2010: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Tetralogic Pharmaceuticals Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $32 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Helga A. Kautsky · Executive Officer
  • John M. Gill · Executive Officer, Director
  • Mark A. McKinlay · Executive Officer
  • Andrew A. Pecora · Director
  • Brenda A. Gavin · Director
  • Douglas A. Reed · Director
  • Harold A. Werner · Director
  • James A. Woody · Director
  • Michael A. Steinmetz · Director
  • Paul A. Schmitt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John M. Gill, President & CEO. Newest notice filed Aug 10, 2010. Read the notice at the SEC.

equitySEC
Mar 2010$2 MNo. 2$2 to $10 million

Tetralogic Pharmaceuticals Corp.: Raise no. 2, Mar 2010

Investors in this round

13 investors had bought by the notice of Mar 24, 2010: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Tetralogic Pharmaceuticals Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John M. Gill · Executive Officer, Director
  • Mark A. McKinlay · Executive Officer
  • Andrew A. Pecora · Director
  • Brenda A. Gavin · Director
  • George A. McLendon · Director
  • Harold A. Werner · Director
  • Jack A. Lasersohn · Director
  • Jim A. Woody · Director
  • Paul A. Schmitt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John M. Gill, President. Newest notice filed Mar 24, 2010. Read the notice at the SEC.

debt, optionsSEC
Nov 2009$2 MNo. 1$2 to $10 million

Tetralogic Pharmaceuticals Corp.: Raise no. 1, Nov 2009

Investors in this round

13 investors had bought by the notice of Mar 24, 2010: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Tetralogic Pharmaceuticals Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John M. Gill · Executive Officer, Director
  • Mark A. McKinlay · Executive Officer
  • Andrew A. Pecora · Director
  • Brenda A. Gavin · Director
  • George A. McLendon · Director
  • Harold A. Werner · Director
  • Jack A. Lasersohn · Director
  • Jim A. Woody · Director
  • Paul A. Schmitt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John M. Gill, President. Newest notice filed Mar 24, 2010 (1 amendment). Read the notice at the SEC.

debt, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tetralogic Pharmaceuticals Corp. chose not to state its revenue in its newest notice of a funding round (Dec 2012).

    SEC Form D · Dec 2012

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2012

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in Tetralogic Pharmaceuticals Corp.
InvestorKindAmountRoundRoleSource
Amgen IncCompanynot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Amgen Ventures LLCVenture capitalnot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Clarus Lifesciences II, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Clarus Ventures II GP, L.P.Venture capitalnot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Clarus Ventures II, LLCVenture capitalnot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
HealthCare Partners VII, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Healthcare Ventures VII LPVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tetralogic Pharmaceuticals Corp.
NameRoleNamed in
David E. WengExecutive officerDec 2012
James E. GoldschmidtExecutive officerDec 2012
John M. GillExecutive officerDec 2012
Helga A. KautskyExecutive officerMay 2011
Mark A. McKinlayExecutive officerMay 2011
Andrew E. PecoraDirectorDec 2012
Brenda E. GavinDirectorDec 2012
Douglas E. OnsiDirectorDec 2012
Douglas E. ReedDirectorDec 2012
James E. WoodyDirectorDec 2012
John M. GillDirectorDec 2012
Michael E. SteinmetzDirectorDec 2012
Paul E. SchmittDirectorDec 2012
Andrew A. PecoraDirectorMay 2011
Brenda A. GavinDirectorMay 2011
Douglas A. ReedDirectorMay 2011
Harold A. WernerDirectorMay 2011
James A. WoodyDirectorMay 2011
Michael A. SteinmetzDirectorMay 2011
Paul A. SchmittDirectorMay 2011
George A. McLendonDirectorMar 2010
Jack A. LasersohnDirectorMar 2010
Jim A. WoodyDirectorMar 2010